The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 14, 2025
Filed:
Mar. 23, 2021
Applicant:
Acceleron Pharma Inc., Cambridge, MA (US);
Inventors:
Ravindra Kumar, Acton, MA (US);
Rajasekhar Naga Venkata Sai Suragani, Wrentham, MA (US);
Assignee:
ACCELERON PHARMA INC., Cambridge, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/17 (2006.01); A61K 31/519 (2006.01); A61K 45/06 (2006.01); A61P 7/00 (2006.01); A61P 7/06 (2006.01); C07K 14/71 (2006.01);
U.S. Cl.
CPC ...
A61K 38/179 (2013.01); A61K 31/519 (2013.01); A61K 38/1796 (2013.01); A61K 45/06 (2013.01); A61P 7/00 (2018.01); A61P 7/06 (2018.01); C07K 14/71 (2013.01); C07K 2319/30 (2013.01);
Abstract
In part, the present disclosure relates methods for treating, preventing, or reducing the progression rate and/or severity of myelofibrosis or one or more complications of myelofibrosis (extramedullary hematopoiesis, splenomegaly, anemia, and fibrosis). In certain aspects, the disclosure provides ActRIIB antagonists for use in treating, preventing, or reducing the progression rate and/or severity of one or more complications associated with Janus kinase inhibitor therapy in a patient (e.g., anemia).